US Stock MarketDetailed Quotes

EXAS Exact Sciences

Watchlist
  • 50.180
  • -1.100-2.15%
Close Feb 25 16:00 ET
  • 50.120
  • -0.060-0.12%
Post 18:38 ET
9.32BMarket Cap-8.98P/E (TTM)

About Exact Sciences Company

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Company Profile

SymbolEXAS
Company NameExact Sciences
Listing DateJan 31, 2001
Issue Price14.00
Founded1995
CEOMr. Kevin T. Conroy
MarketNASDAQ
Employees7000
Fiscal Year Ends12-31
Address5505 Endeavor Lane
CityMadison
ProvinceWisconsin
CountryUnited States of America
Zip Code53719
Phone1-608-284-5700

Company Executives

  • Name
  • Position
  • Salary
  • Kevin T. Conroy
  • Chairman of the Board, President and Chief Executive Officer
  • 16.12M
  • Aaron Bloomer
  • Executive Vice President, Chief Financial Officer and Principal Accounting Officer
  • --
  • Jacob Orville
  • Executive Vice President and General Manager, Screening
  • 3.67M
  • Brian Baranick
  • Executive Vice President and General Manager, Precision Oncology
  • 3.57M
  • Sarah Condella
  • Executive Vice President, Human Resources
  • --
  • James Herriott
  • Senior Vice President, General Counsel and Secretary
  • --
  • D. Scott Coward
  • Director
  • 1.47M
  • Kimberly J. Popovits
  • Director
  • --
  • Shacey Petrovic
  • Independent Director
  • 401.25K
  • James E. Doyle
  • Lead Independent Director
  • 442.75K
  • Kathleen Sebelius
  • Independent Director
  • 411.75K
  • Daniel Joseph Levangie
  • Independent Director
  • 408.75K
  • Michael J. Barber
  • Independent Director
  • --
  • Paul J. Clancy
  • Independent Director
  • 417.75K
  • Katherine S. Zanotti
  • Independent Director
  • 406.25K

Trending Stocks

Discussing
Tesla's earnings caused fluctuations, what's your market outlook?
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More